ArticleEye (London, England)2026
Correlation between blood glucose levels and endophthalmitis risk after intravitreal injections of anti-vascular endothelial growth factor.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsTo evaluate the association between blood glucose levels and the development of endophthalmitis in patients receiving anti-vascular endothelial growth factor (VEGF) injections.
methodsRetrospective analysis of electronic medical records of patients who received anti-VEGF injections at four centres within a single ophthalmic institution. Pre-injection, random, fasting, and post-prandial blood glucose levels were analysed with respect to the development of endophthalmitis. The association between blood glucose levels, and the presence and duration of diabetes mellitus (DM), and the development of post-injection endophthalmitis was determined.
resultsThis study included 60,707 injections administered to 25,751 patients, 48.73% of whom had DM. Sixteen patients developed post-injection endophthalmitis; incidence rate was 6 per 10,000 patients (0.06%) and 2 per 10,000 injections (0.03%). A higher proportion of patients with endophthalmitis had DM (68.75%), compared to those without endophthalmitis (48.72%). The presence of diabetes had a significant association with post-injection endophthalmitis (OR 5.05, 95% CI 1.82-16.27, P-0.00). Regarding duration of diabetes, there was no statistically significant difference between patients with and without endophthalmitis (OR 3.33, P = 0.281). Compared to patients without endophthalmitis, those with endophthalmitis had similar random blood glucose levels (150.89 ± 63.75 mg/dL vs. 141 ± 64 mg/dL), similar fasting blood glucose levels (135.86 ± 32.73 mg/dL vs. 132 ± 53 mg/dL), and higher post-prandial levels (208.2 ± 69.12 mg/dL vs. 188 ± 56 mg/dL), but it was not statistically significant.
conclusionWe found a significant association between presence of diabetes and post-injection endophthalmitis. Immediate pre-injection blood glucose levels were not associated with post-injection endophthalmitis but the duration of diabetes was longer in patients developing endophthalmitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.